Basit öğe kaydını göster

dc.contributor.authorBelet, Nursen
dc.contributor.authorTop, Ayse
dc.contributor.authorTerzi, Ozlem
dc.contributor.authorArslan, Hatice Nilden
dc.contributor.authorBaysal, Kemal
dc.contributor.authorSensoy, Gulnar
dc.date.accessioned2020-06-21T13:56:54Z
dc.date.available2020-06-21T13:56:54Z
dc.date.issued2014
dc.identifier.issn0891-3668
dc.identifier.issn1532-0987
dc.identifier.urihttps://doi.org/10.1097/INF.0000000000000281
dc.identifier.urihttps://hdl.handle.net/20.500.12712/15064
dc.descriptionWOS: 000339275500003en_US
dc.descriptionPubMed: 24463803en_US
dc.description.abstractBackground: Crimean-Congo hemorrhagic fever (CCHF) is endemic in some regions of our country. It is seen in all age groups; however, its prevalance is low in children. The studies on CCHF have been mostly in adults. The aim of this study was to evaluate the epidemiologic, demographic, clinical and laboratory findings of children with CCHF. Methods: Between May 2008 and September 2011, the medical records of patients who were admitted to the Children Infectious Diseases Service of Ondokuz Mayis University School of Medicine with positive blood IgM by enzyme-linked immunosorbent assay or polymerase chain reaction positive for CCHF were retrospectively evaluated. Epidemiologic and demographic features, clinical and laboratory data and therapy were recorded. Results: Fifty-four patients with the diagnosis of CCHF were recorded between May 2008 and September 2011. Main symptoms during hospital admission were fever (98%), vomiting (59%), headache (39%), nausea (39%), diarrhea (22%), abdominal pain (22%), bleeding (22%) and rash (20%). During admission, thrombocytopenia was found in 74%, elevated aspartate aminotransferase in 61%, leucopenia in 57%, elevated creatine kinase (33%) and alanine aminotransaminase (29%), and prolonged prothrombin time and partial thromboplastine time in 28% were noted. Thirty-nine patients received ribavirin treatment. During clinical follow up, bradycardia was recorded in 18 patients (33%) all of whom received ribavirin treatment. One patient died. Conclusions: This study reports the largest series of children with CCHF and the first to describe bradycardia associated with ribavirin therapy.en_US
dc.language.isoengen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.isversionof10.1097/INF.0000000000000281en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCrimean-Congo hemorrhagic feveren_US
dc.subjectchildrenen_US
dc.subjectbradycardiaen_US
dc.subjectribavirinen_US
dc.titleEvaluation of Children with Crimean-Congo Hemorrhagic Fever in the Central Blacksea Regionen_US
dc.typearticleen_US
dc.contributor.departmentOMÜen_US
dc.identifier.volume33en_US
dc.identifier.issue8en_US
dc.identifier.startpageE194en_US
dc.identifier.endpageE197en_US
dc.relation.journalPediatric Infectious Disease Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster